Azenta AZTA Available-for-Sale Debt Securities - Amortized Cost

Available-for-Sale Debt Securities - Amortized Cost at other companies

Twist Bioscience CorporationTWST

$49M+5.0%

BioLife SolutionsBLFS

$88.79M+118%

Bio-Rad LaboratoriesBIO

——

Other financials

Income statement

See full

Revenue$144.8M+1.0%

Gross profit$62.0M-1.2%

Operating income-$165.8M-811%

Net income-$160.8M-237%

EPS (diluted)-$3.49-236%

Balance sheet

See full

Cash & equivalents$125.2M—

Total debt$55.7M—

Total equity$1.6B-8.3%

Total assets$1.9B—

Cash flow

See full

Operating cash flow$13.5M-6.2%

CapEx$7.4M-0.1%

Free cash flow$6.1M-12.7%

Valuation

See full

Market cap$1.1B-19.0%

Enterprise value$1.03B—

P/S1.8×-0.3×

Profitability

See full

Gross margin40%-1.0pp

Operating margin-31.6%-59.7pp

Net margin-29.1%-80.7pp

FCF margin8.6%—

Returns & leverage

See full

Return on equity-10.7%-22.4pp

Debt / equity0×—

Current ratio2.8×—

Where this comes from

Reported directly by Azenta in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost.

The official record: Azenta’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Azenta's available-for-sale debt securities - amortized cost.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Azenta's available-for-sale debt securities - amortized cost?: Azenta (AZTA) reported available-for-sale debt securities - amortized cost of $146.51M in Q1 2026.
What does available-for-sale debt securities - amortized cost mean?: This is the cost basis of debt securities classified as available-for-sale, adjusted for amortization of premiums or discounts. It represents the value of the investment portfolio before accounting for current market price fluctuations. This provides a baseline for evaluating the performance of the company's liquid investment strategy.